The boundary between animal health and human health has never been more consequential. Diseases that jump from animals to people, from H5N1 avian influenza spreading through dairy cattle to emerging bacterial threats, represent one of the most persistent and unpredictable challenges in global public health. Sustained institutional capacity to study these pathogens before they become crises is exactly what federal research investment is meant to build.
Kansas State University has secured $11.4 million in continued National Institutes of Health funding to support the Center on Emerging and Zoonotic Infectious Diseases (CEZID), through April 2031. The NIH award extends the center into its second five-year phase and signals confidence in the research infrastructure and scientific pipeline K-State has built since CEZID launched in 2020.
CEZID is housed in K-State’s College of Veterinary Medicine and directed by Juergen A. Richt, a Regents and university distinguished professor whose work spans high-consequence pathogens including H5N1 influenza, African swine fever virus, mpox, and SARS-CoV-2. The center’s mission is straightforward: build the scientific workforce and shared laboratory infrastructure needed to understand how dangerous pathogens cause disease, how they move between animals and humans, and how they can be stopped.
K-State sits within a major agricultural corridor and operates some of the country’s most capable high-containment research facilities, including the Biosecurity Research Institute, a BSL-3 and agricultural BSL-3 facility on the Manhattan campus. The nearby National Bio and Agro-Defense Facility further concentrates expertise and infrastructure in the region. CEZID links the university’s infectious disease research to this broader ecosystem, creating a regional hub with national reach.
In its first five years, CEZID investigators submitted over 100 research proposals and received 30 awards totaling approximately $18 million in external funding. Phase 2 will pursue four research tracks examining virulence factors and host-pathogen interactions across a range of pathogens. Current projects include studies of Borrelia burgdorferi, the bacterium responsible for Lyme disease; how obesity alters influenza severity through multi-omics analysis; sporulation mechanisms in Clostridioides difficile, a major source of hospital-acquired infection; and a novel coronavirus vaccine strategy using genetic deoptimization to render viruses harmless.
Two shared laboratory cores will continue operating throughout Phase 2. The Animal Model/Pathology Core provides BSL-2 and BSL-3 research capabilities, animal model development, and pathology expertise. The Molecular and Cellular Biology Core offers next-generation sequencing, flow cytometry, and spatial transcriptomics. Both cores were integrated into K-State’s Biomedical Core Facilities during Phase 1, extending access to investigators across the university and the broader regional research community. The Regional Scientific Network, which connects CEZID investigators with collaborators at the University of Kansas and the University of Kansas Medical Center, will expand as well.
The ongoing H5N1 situation in U.S. dairy herds, which CEZID researchers have studied directly, illustrates how quickly an animal health problem can become a potential human health emergency. The five-year renewal ensures K-State retains and deepens one of the country’s more capable regional centers for this work.
Sources and further information:
CEZID receives $11.4 million in continued NIH funding – K-State Today
This content was researched and sourced by Global Biodefense editors and reported with Claude AI assistance for drafting and editing.